Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.

2.

Secondary thrombotic microangiopathy with severely reduced ADAMTS13 activity in a patient with Capnocytophaga canimorsus sepsis: a case report.

Smeets NJL, Fijnheer R, Sebastian S, De Mast Q.

Transfusion. 2018 Oct;58(10):2426-2429. doi: 10.1111/trf.14829. Epub 2018 Sep 17.

PMID:
30222856
3.

Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma.

Clark CC, Mebius MM, de Maat S, Tielens AGM, de Groot PG, Urbanus RT, Fijnheer R, Hazenberg BPC, van Hellemond JJ, Maas C.

Thromb Haemost. 2018 Mar;118(3):471-479. doi: 10.1055/s-0038-1627460. Epub 2018 Mar 13.

PMID:
29534248
4.

The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages.

Verbij FC, Sorvillo N, Kaijen PHP, Hrdinova J, Peyron I, Fijnheer R, Ten Brinke A, Meijer AB, van Alphen FPJ, van den Berg TK, Graversen JJH, Moestrup SK, Voorberg J.

Blood Adv. 2017 Jan 16;1(5):293-305. doi: 10.1182/bloodadvances.2016001321. eCollection 2017 Jan 24.

5.

Agonist-induced platelet reactivity correlates with bleeding in haemato-oncological patients.

Batman B, van Bladel ER, van Hamersveld M, Pasker-de Jong PCM, Korporaal SJA, Urbanus RT, Roest M, Boven LA, Fijnheer R.

Vox Sang. 2017 Nov;112(8):773-779. doi: 10.1111/vox.12557. Epub 2017 Sep 29.

PMID:
28960383
6.

Thrombotic thrombocytopenic purpura related to ADAMTS13 deficiency, and successful treatment in a chimpanzee (Pan troglodytes verus).

van Bolhuis H, Wolters M, de Boer M, Fijnheer R, van Zijll Langhout M, Niphuis H, Eckmann C.

J Med Primatol. 2017 Oct;46(5):267-270. doi: 10.1111/jmp.12278. Epub 2017 May 26.

PMID:
28547839
7.

Where Does Diffuse Large B-Cell Lymphoma Relapse?

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

J Comput Assist Tomogr. 2016 Jul-Aug;40(4):531-6. doi: 10.1097/RCT.0000000000000395.

PMID:
26966953
8.

Functional recovery of stored platelets after transfusion.

Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M.

Transfusion. 2016 May;56(5):1030-7. doi: 10.1111/trf.13544. Epub 2016 Mar 2.

PMID:
26935249
9.

CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides.

Verbij FC, Turksma AW, de Heij F, Kaijen P, Lardy N, Fijnheer R, Sorvillo N, ten Brinke A, Voorberg J.

Blood. 2016 Mar 24;127(12):1606-9. doi: 10.1182/blood-2015-10-668053. Epub 2016 Jan 8.

10.

Computed Tomography Observer Agreement in Staging Malignant Lymphoma.

de Jong A, Kwee TC, Quarles van Ufford HM, Beek FJ, Quekel LG, de Klerk JM, Zijlstra JM, Fijnheer R, Ludwig I, Kersten MJ, Stoker J, Nievelstein RA.

J Comput Assist Tomogr. 2016 Mar-Apr;40(2):261-5. doi: 10.1097/RCT.0000000000000338.

PMID:
26599962
11.

Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.

Tersteeg C, Fijnheer R, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de Maat S, Maas C.

Semin Thromb Hemost. 2016 Feb;42(1):9-17. doi: 10.1055/s-0035-1564838. Epub 2015 Nov 23. Review.

PMID:
26595154
12.

Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma.

Adams HJA, de Klerk JMH, Fijnheer R, Heggelman BGF, Dubois SV, Nievelstein RAJ, Kwee TC.

Eur J Radiol. 2016 Jan;85(1):304-309. doi: 10.1016/j.ejrad.2015.09.016. Epub 2015 Sep 21.

PMID:
26515992
13.

Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Nucl Med Commun. 2016 Jan;37(1):23-9. doi: 10.1097/MNM.0000000000000400.

PMID:
26440567
14.

Disappearing acts of ADAMTS13.

Voorberg J, Verbij FC, Fijnheer R.

EBioMedicine. 2015 Jul 10;2(8):800-1. doi: 10.1016/j.ebiom.2015.07.013. eCollection 2015 Aug. Review. No abstract available.

15.

Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):671-9. doi: 10.1016/j.clml.2015.07.639. Epub 2015 Aug 5.

PMID:
26361646
16.

Is asymptomatic malaria really asymptomatic? Hematological, vascular and inflammatory effects of asymptomatic malaria parasitemia.

de Mast Q, Brouwers J, Syafruddin D, Bousema T, Baidjoe AY, de Groot PG, van der Ven AJ, Fijnheer R.

J Infect. 2015 Nov;71(5):587-96. doi: 10.1016/j.jinf.2015.08.005. Epub 2015 Aug 21.

PMID:
26304688
17.

Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Acta Radiol. 2016 Jun;57(6):733-41. doi: 10.1177/0284185115598809. Epub 2015 Aug 20.

PMID:
26297729
18.

Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.

Krabbe JG, Kemna EW, Strunk AL, Jobse PA, Kramer PA, Dikkeschei LD, van den Heuvel LP, Fijnheer R, Verdonck LF.

Int J Hematol. 2015 Oct;102(4):477-81. doi: 10.1007/s12185-015-1849-2. Epub 2015 Aug 13.

PMID:
26267233
19.

Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

J Comput Assist Tomogr. 2015 Sep-Oct;39(5):810-5. doi: 10.1097/RCT.0000000000000270.

PMID:
26035406
20.

Lymphoma grading with FDG-PET/CT readdressed: Direct and timely histopathological correlation study.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Acta Oncol. 2016;55(3):386-90. doi: 10.3109/0284186X.2015.1041652. Epub 2015 May 15. No abstract available.

PMID:
25975211
21.

Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study.

Littooij AS, Kwee TC, de Keizer B, Bruin MC, Coma A, Beek FJ, Fijnheer R, Nievelstein RA.

J Magn Reson Imaging. 2015 Dec;42(6):1646-55. doi: 10.1002/jmri.24938. Epub 2015 May 8.

PMID:
25952024
22.

Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses.

Tunjungputri RN, van der Ven AJ, Riksen N, Rongen G, Tacke S, van den Berg TN, Fijnheer R, Gomes ME, Dinarello CA, van de Veerdonk FL, Gasem MH, Netea MG, Joosten LA, de Groot PG, de Mast Q.

Thromb Haemost. 2015 May;113(5):1035-45. doi: 10.1160/TH14-07-0579. Epub 2015 Feb 26.

PMID:
25716539
23.

False-negative FDG-PET in histologically proven extensive large cell bone marrow involvement in diffuse large B-cell lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Dubois SV, Nievelstein RA, Kwee TC.

Am J Hematol. 2015 Jul;90(7):681. doi: 10.1002/ajh.23986. Epub 2015 May 3. No abstract available.

24.

CT-based versus FDG-PET/CT-based NCCN international prognostic index risk stratification in DLBCL.

Adams HJ, de Klerk JM, Fijnheer R, Dubois SV, Nievelstein RA, Kwee TC.

J Natl Compr Canc Netw. 2015 Feb;13(2):171-6.

PMID:
25691609
25.

Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma.

Littooij AS, Kwee TC, Barber I, Granata C, de Keizer B, Beek FJ, Hobbelink MG, Fijnheer R, Stoker J, Nievelstein RA.

Acta Radiol. 2016 Feb;57(2):142-51. doi: 10.1177/0284185115571657. Epub 2015 Feb 13.

PMID:
25681490
26.

Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Skeletal Radiol. 2015 May;44(5):687-94. doi: 10.1007/s00256-015-2102-z. Epub 2015 Feb 7.

27.

Response to letter regarding article, "plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".

Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.

Circulation. 2015 Jan 13;131(2):e19-20. doi: 10.1161/CIRCULATIONAHA.114.012802. No abstract available.

PMID:
25583061
28.

Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma.

Adams HJA, de Klerk JMH, Fijnheer R, Dubois SV, Nievelstein RAJ, Kwee TC.

Eur J Radiol. 2015 Mar;84(3):372-377. doi: 10.1016/j.ejrad.2014.12.009. Epub 2014 Dec 19.

29.

Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.

Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM.

Eur J Haematol. 2015 Jul;95(1):83-9. doi: 10.1111/ejh.12483. Epub 2015 Feb 1.

PMID:
25537478
30.

Paget's disease of the bone mimicking lymphomatous bone marrow involvement at FDG-PET.

Adams HJ, de Klerk JM, Fijnheer R, Dubois SV, Nievelstein RA, Kwee TC.

Am J Hematol. 2015 Mar;90(3):269-70. doi: 10.1002/ajh.23921. No abstract available.

31.

Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?

Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM.

Acta Radiol. 2015 Oct;56(10):1230-5. doi: 10.1177/0284185114554824. Epub 2014 Nov 11.

PMID:
25387723
32.

Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?

Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM.

Ann Nucl Med. 2015 Feb;29(2):132-7. doi: 10.1007/s12149-014-0920-z. Epub 2014 Oct 28.

PMID:
25348549
33.

Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Eur J Haematol. 2015 Jun;94(6):532-9. doi: 10.1111/ejh.12467. Epub 2015 Mar 13.

PMID:
25311082
34.

Effect of blind bone marrow biopsy on FDG-PET/CT interpretation of the posterior iliac crest in diffuse large B-cell lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Dubois SV, Nievelstein RA, Kwee TC.

Hematol Oncol. 2016 Mar;34(1):52-4. doi: 10.1002/hon.2167. Epub 2014 Oct 10. No abstract available.

PMID:
25308895
35.

Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen.

Tunjungputri RN, Van Der Ven AJ, Schonsberg A, Mathan TS, Koopmans P, Roest M, Fijnheer R, Groot PG, de Mast Q.

AIDS. 2014 Sep 10;28(14):2091-6. doi: 10.1097/QAD.0000000000000415.

PMID:
25265076
36.

Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Acta Oncol. 2015 Jan;54(1):67-72. doi: 10.3109/0284186X.2014.958531. Epub 2014 Sep 29.

PMID:
25263078
37.

Acquired TTP: ADAMTS13 meets the immune system.

Verbij FC, Fijnheer R, Voorberg J, Sorvillo N.

Blood Rev. 2014 Nov;28(6):227-34. doi: 10.1016/j.blre.2014.07.004. Epub 2014 Aug 15. Review.

PMID:
25213289
38.

Identification of N-linked glycosylation and putative O-fucosylation, C-mannosylation sites in plasma derived ADAMTS13.

Sorvillo N, Kaijen PH, Matsumoto M, Fujimura Y, van der Zwaan C, Verbij FC, Pos W, Fijnheer R, Voorberg J, Meijer AB.

J Thromb Haemost. 2014 May;12(5):670-9.

PMID:
24977290
39.

Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study.

Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Blase PE, Nievelstein RA, de Klerk JM.

Skeletal Radiol. 2014 Sep;43(9):1231-6. doi: 10.1007/s00256-014-1919-1. Epub 2014 Jun 6.

PMID:
24902511
40.

Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.

de Jong A, Kwee TC, de Klerk JM, Adam JA, de Keizer B, Fijnheer R, Kersten MJ, Ludwig I, Jauw YW, Zijlstra JM, Pieters-Van den Bos IC, Stoker J, Hoekstra OS, Nievelstein RA.

Am J Nucl Med Mol Imaging. 2014 Apr 25;4(3):231-8. eCollection 2014.

41.

Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.

Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM.

Am J Hematol. 2014 Jul;89(7):726-31. doi: 10.1002/ajh.23730. Epub 2014 Apr 18.

42.

Platelet function alterations in dengue are associated with plasma leakage.

Michels M, Alisjahbana B, De Groot PG, Indrati AR, Fijnheer R, Puspita M, Dewi IM, van de Wijer L, de Boer EM, Roest M, van der Ven AJ, de Mast Q.

Thromb Haemost. 2014 Aug;112(2):352-62. doi: 10.1160/TH14-01-0056. Epub 2014 Apr 3.

PMID:
24695691
43.

Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?

van Hamersvelt HP, Kwee TC, Fijnheer R, Beek FJ, de Klerk JM, Nievelstein RA.

J Comput Assist Tomogr. 2014 Jul-Aug;38(4):620-5. doi: 10.1097/RCT.0000000000000067.

PMID:
24681861
44.

Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.

Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.

Circulation. 2014 Mar 25;129(12):1320-31. doi: 10.1161/CIRCULATIONAHA.113.006727. Epub 2014 Jan 21.

PMID:
24449821
45.

Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?

Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, Nievelstein RA.

Ann Oncol. 2014 May;25(5):921-7. doi: 10.1093/annonc/mdt533. Epub 2013 Dec 18. Review.

PMID:
24351400
46.

Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy.

Adams HJ, Kwee TC, Lokhorst HM, Westerweel PE, Fijnheer R, Kersten MJ, Verkooijen HM, Stoker J, Nievelstein RA.

J Magn Reson Imaging. 2014 Jun;39(6):1394-400. doi: 10.1002/jmri.24318. Epub 2013 Nov 14.

PMID:
24310955
47.

Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study.

Kwee TC, Vermoolen MA, Akkerman EA, Kersten MJ, Fijnheer R, Ludwig I, Beek FJ, van Leeuwen MS, Bierings MB, Bruin MC, Zsíros J, Quarles van Ufford HM, de Klerk JM, Adam J, Stoker J, Uiterwaal CS, Nievelstein RA.

J Magn Reson Imaging. 2014 Jul;40(1):26-36. doi: 10.1002/jmri.24356. Epub 2013 Oct 31.

PMID:
24307538
48.

FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.

Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Nievelstein RA.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):565-74. doi: 10.1007/s00259-013-2623-4. Epub 2013 Nov 27. Review.

PMID:
24281821
49.

Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series.

Russcher M, Josephus Jitta N, Kraaijenhagen RJ, Fijnheer R, Pasker-de Jong PC, Gaillard CA.

Clin Kidney J. 2013 Oct;6(5):473-7. doi: 10.1093/ckj/sft083. Epub 2013 Sep 5.

50.

Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers.

Brouwers J, Noviyanti R, Fijnheer R, de Groot PG, Trianty L, Mudaliana S, Roest M, Syafruddin D, van der Ven A, de Mast Q.

PLoS One. 2013 Jun 3;8(6):e64850. doi: 10.1371/journal.pone.0064850. Print 2014.

Supplemental Content

Loading ...
Support Center